Abstract
The need of plasma therapeutic proteins continues to increase in global level, even with the development of a number of recombinant products. IgG is currently the most important hemoderivative and is responsible for 50% of the world market. The interest in the plasma derived IgM is increasing due to the increasing of results suggesting that this protein can present anti-inflammatory and i…